Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 13/20 | 0.57 |
| ▸ | CNR2 | P34972 | 8/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4215280 | 0.81 | CNR1 (0.56) | CNR1CNR2 | |
| SCHEMBL6335025 | 0.77 | CNR1 (0.41) | CNR1CNR2 | |
| Lithium Ion SCHEMBL4220249 | 0.76 | CNR1 (0.40) | CNR1CNR2 | |
| SCHEMBL4220252 | 0.76 | CNR1 (0.40) | CNR1CNR2 | |
| SCHEMBL4213596 | 0.75 | CNR1 (0.53) | CNR1CNR2 | |
| SCHEMBL4212958 | 0.73 | CNR1 (0.43) | CNR1CNR2RAB9AMAPT | |
| SCHEMBL4508080 | 0.73 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL4503198 | 0.73 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL4503196 | 0.73 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL3366001 | 0.72 | CNR1 (0.67) | CNR1CNR2ALDH1A1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725536-B1 | IMIDAZOLINE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2008-10-15 | — | — | EP | claimed |
| US-7173044-B2 | Imidazoline derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2007-02-06 | — | — | US | claimed |
| US-7495108-B2 | Imidazoline derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS, B.V. | 2009-02-24 | — | — | US | disclosed |
| US-7495108-B2 | Imidazoline derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS, B.V. | 2009-02-24 | — | — | US | disclosed |
| US-7495108-B2 | Imidazoline derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS, B.V. | 2009-02-24 | — | — | US | disclosed |
| EP-1725536-B1 | IMIDAZOLINE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2008-10-15 | — | — | EP | disclosed |
| US-20070135492-A1 | Imidazoline derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS, B.V,. | 2007-06-14 | — | — | US | disclosed |
| US-20070135492-A1 | Imidazoline derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS, B.V,. | 2007-06-14 | — | — | US | disclosed |
| US-20070135492-A1 | Imidazoline derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS, B.V,. | 2007-06-14 | — | — | US | disclosed |
| US-7173044-B2 | Imidazoline derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2007-02-06 | — | — | US | disclosed |
| US-7173044-B2 | Imidazoline derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2007-02-06 | — | — | US | disclosed |
| US-7173044-B2 | Imidazoline derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2007-02-06 | — | — | US | disclosed |
| EP-1725536-A2 | IMIDAZOLINE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | Solvay Pharmaceuticals B.V. (NL) | 2006-11-29 | — | — | EP | disclosed |
| US-20060241152-A9 | Imidazoline derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. | 2006-10-26 | — | — | US | disclosed |
| WO-2005080345-A2 | IMIDAZOLINE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-09-01 | — | — | WO | disclosed |
| US-20050187259-A1 | Imidazoline derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135492-A1 | Imidazoline derivatives having CB1-antagonistic activity | CNR2, CNR1, GRIN2C | CNR1 2/4885CNR2 1/4885ALDH1A1 2794/4885 |
| US-20050187259-A1 | Imidazoline derivatives having CB1-antagonistic activity | CNR2, CNR1, GRIN2C | CNR1 2/4885CNR2 1/4885ALDH1A1 2654/4885 |
| US-20060241152-A9 | Imidazoline derivatives having CB1-antagonistic activity | CNR2, CNR1, GRIN2C | CNR1 2/4885CNR2 1/4885ALDH1A1 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.